MIMS Urgent Update - Oral COVID-19 Drugs
 


The TGA has granted provisional approval for the use of the following Oral COVID-19 Drugs. These will be included and searchable in MIMS from 1st of March 2022. Until then, Full Product Information (PI) and Consumer Medicines Information (CMI) can be accessed using these links.

Molnupiravir (Lagevrio): PI | CMI

Nirmatrelvir + Ritonavir (Paxlovid): PI | CMI




 

To contact MIMS editorial please email editorial@mims.com.au. To enquire about purchasing a product please contact MIMS Customer service on 1800 800 629 or email subscriptions@mims.com.au. For more information about MIMS, please see www.mims.com.au.

 
Copyright © 2022 MIMS Australia Pty Ltd. All rights reserved.
Our mailing address is:
MIMS Australia, Suite 302, Level 3, 53 Berry Street, North Sydney NSW 2060, Phone: 1800 800 629